Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Athol › NPI 1336120047
Physician

Athol Memorial Hospital Incorporated

Athol Memorial Hospital Incorporated was paid $30.77M by Medicaid between Jan 2018 and Dec 2024, across 235 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 16% of everything it billed.

33Billing provider infoATHOL MEMORIAL HOSPITAL INCORPORATED
ATHOL, MA 01331
33aNPI1336120047assigned 11/09/2005
33bProvider typeBody Imaging Physician
28Total paid$30.77M
24GClaims545,811
24DCodes billed235
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Body Imaging Physician providers in Massachusetts

Rank by total paid#1 of 18
Median peer was paid$7K
This provider vs. median4,397×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201869,975$2.83M
201980,443$3.80M
202071,351$4.41M
202187,963$5.11M
2022103,518$5.43M
202375,256$5.31M
2024incomplete57,305$3.88M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 16% 16,998 14,301 $4.82M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 14% 15,269 13,336 $4.26M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 11% 19,081 16,112 $3.48M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 11% 19,623 14,276 $3.32M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 10% 20,553 16,797 $3.11M
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 6.1% 15,288 4,303 $1.86M
96361 Intravenous infusion, hydration; each additional hour 5.5% 4,212 3,589 $1.69M
99282 Emergency department visit for the evaluation and management, low to moderate severity 2.4% 3,787 3,084 $731K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.8% 4,247 3,490 $547K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 1.7% 5,061 4,409 $529K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1.6% 8,244 6,611 $484K
70450 Computed tomography, head or brain; without contrast material 1.5% 3,020 2,661 $468K
223 more codes
74177 Computed tomography, abdomen and pelvis; with contrast material 1.4% 2,181 $429K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 1,041 $306K
99203 Doctor's office visit, new patient (routine) <1% 1,243 $291K
71046 Radiologic examination, chest; 2 views <1% 6,689 $242K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 2,957 $210K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 5,859 $205K
G0378 Hospital observation service, per hour <1% 1,319 $203K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 6,737 $195K
99204 Doctor's office visit, new patient (more involved) <1% 766 $164K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 1,698 $150K
77067 Screening mammography, bilateral, including computer-aided detection <1% 1,072 $143K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 2,889 $135K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 29,569 $131K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 6,839 $121K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 671 $103K
97161 <1% 702 $84K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 9,265 $83K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 3,580 $83K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 471 $82K
96127 <1% 2,956 $81K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 580 $79K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 55 $73K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 12,865 $69K
80053 Comprehensive metabolic panel <1% 25,391 $68K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 945 $61K
ATP14 <1% 12,783 $58K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 3,308 $57K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 280 $56K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 4,108 $52K
84443 Thyroid stimulating hormone (TSH) <1% 5,618 $45K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 432 $45K
73630 <1% 1,602 $44K
83036 Hemoglobin; glycosylated (A1C) <1% 6,701 $41K
97162 <1% 363 $37K
84484 <1% 6,983 $35K
99406 <1% 911 $33K
90686 <1% 326 $32K
80050 General health panel <1% 2,101 $32K
83690 <1% 6,981 $31K
93010 Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only <1% 8,844 $29K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 149 $28K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 302 $27K
82607 <1% 3,153 $26K
80061 Lipid panel <1% 7,586 $26K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 106 $26K
87143 <1% 4,382 $25K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 85 $24K
73610 <1% 897 $24K
82728 <1% 3,197 $23K
97035 <1% 289 $23K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,941 $22K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 2,140 $22K
83880 <1% 2,406 $21K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 479 $21K
71045 Radiologic examination, chest; single view <1% 4,873 $21K
94760 <1% 20,165 $20K
84466 <1% 2,824 $20K
36415 Collection of venous blood by venipuncture <1% 32,846 $20K
80048 Basic metabolic panel (calcium, ionized) <1% 8,697 $18K
71275 Computed tomographic angiography, chest, with contrast material <1% 118 $16K
90839 <1% 272 $16K
ATP08 <1% 5,230 $15K
73030 <1% 512 $15K
97750 <1% 266 $14K
82746 <1% 1,857 $14K
87070 <1% 2,406 $14K
ATP15 <1% 2,640 $14K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,549 $13K
99395 Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years <1% 130 $13K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 296 $13K
87077 <1% 2,970 $13K
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years <1% 93 $12K
72100 <1% 216 $12K
85027 <1% 3,823 $12K
83735 <1% 3,518 $12K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 71 $12K
83540 <1% 3,264 $12K
87186 <1% 2,480 $11K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 265 $11K
87634 <1% 454 $11K
99223 Prolong inpt eval add15 m <1% 72 $10K
81001 <1% 6,676 $10K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 408 $10K
95831 <1% 269 $9K
87088 <1% 2,188 $9K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 342 $9K
84702 <1% 936 $9K
ATP17 <1% 2,451 $9K
96110 Developmental screening, with scoring and documentation, per standardized instrument <1% 28 $9K
73130 <1% 397 $9K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 458 $9K
74019 <1% 115 $8K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 414 $8K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 924 $8K
85610 <1% 4,476 $8K
96375 Therapeutic injection; each additional sequential IV push <1% 6,891 $8K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 53 $8K
71250 <1% 187 $7K
99218 <1% 237 $7K
90460 Immunization administration through 18 years of age via any route, first or only component <1% 489 $7K
99215 Doctor's office visit, returning patient (complex) <1% 38 $7K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 3,657 $7K
87040 <1% 1,541 $6K
73562 <1% 270 $6K
81025 <1% 1,235 $6K
76830 Ultrasound, transvaginal <1% 14 $6K
73110 <1% 258 $6K
ATP03 <1% 1,292 $6K
72125 Computed tomography, cervical spine; without contrast material <1% 175 $6K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 520 $5K
99220 <1% 38 $5K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 837 $5K
76770 <1% 16 $5K
73560 <1% 26 $5K
86803 <1% 594 $5K
94664 <1% 1,062 $4K
81003 <1% 3,951 $4K
82248 <1% 3,006 $4K
90715 <1% 82 $4K
82948 <1% 1,810 $4K
81002 <1% 1,692 $3K
84439 <1% 680 $3K
S0302 Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) <1% 121 $3K
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 267 $3K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) <1% 81 $3K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 5,056 $3K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 740 $3K
97803 <1% 24 $3K
83605 <1% 834 $3K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 3,691 $2K
82043 <1% 942 $2K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 592 $2K
86140 <1% 842 $2K
90656 <1% 33 $2K
87807 <1% 302 $2K
94060 <1% 12 $2K
82570 <1% 821 $2K
83970 <1% 93 $1K
85007 <1% 901 $1K
85379 <1% 299 $1K
82805 <1% 55 $1K
85018 <1% 1,206 $1K
85014 <1% 1,204 $1K
97535 Self-care/home management training, each 15 minutes <1% 14 $1K
94761 <1% 5,497 $1K
84146 <1% 70 $1K
83655 <1% 104 $1K
86618 <1% 99 $1K
93041 <1% 2,839 $1K
85651 <1% 629 $967.16
87340 <1% 146 $935.34
12001 <1% 26 $933.70
71271 <1% 13 $832.92
73502 <1% 46 $768.60
85730 <1% 401 $740.40
85652 <1% 602 $709.83
S9485 Crisis intervention mental health services, per diem <1% 29 $695.29
82150 <1% 144 $592.73
84153 <1% 100 $584.50
84703 <1% 105 $567.34
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 476 $511.91
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 24 $458.14
85049 <1% 187 $451.41
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 523 $447.25
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 26 $430.64
80076 <1% 584 $366.99
82550 <1% 229 $365.18
J2270 Injection, morphine sulfate, up to 10 mg <1% 949 $361.52
73564 <1% 21 $355.95
81000 <1% 161 $259.37
84436 <1% 43 $254.88
86317 <1% 30 $251.18
84100 <1% 847 $248.87
86141 <1% 57 $244.75
J3475 Injection, magnesium sulfate, per 500 mg <1% 37 $213.70
83615 <1% 187 $210.85
84480 <1% 16 $189.93
ATP16 <1% 105 $174.24
11721 <1% 46 $152.60
ATP07 <1% 66 $151.74
ATP04 <1% 15 $108.60
86038 <1% 13 $99.18
83704 <1% 12 $97.62
99232 Hospital visit by a doctor, follow-up day <1% 55 $97.57
J2060 Injection, lorazepam, 2 mg <1% 747 $86.14
96376 <1% 935 $79.17
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg <1% 13 $65.61
82010 <1% 14 $57.68
83721 <1% 81 $54.51
87046 <1% 13 $48.70
82172 <1% 12 $47.97
83695 <1% 13 $40.05
85045 <1% 27 $40.04
ATP02 <1% 21 $32.22
99000 <1% 75 $26.63
82565 <1% 181 $25.84
84460 <1% 298 $23.35
82803 <1% 14 $19.95
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 789 $19.70
80320 <1% 401 $19.55
J1170 Injection, hydromorphone, up to 4 mg <1% 31 $17.39
84450 0% 68 $0.00
J1200 Injection, diphenhydramine hcl, up to 50 mg 0% 141 $0.00
84145 0% 74 $0.00
G9744 Patient not eligible due to active diagnosis of hypertension 0% 351 $0.00
80143 0% 17 $0.00
G8985 Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 17 $0.00
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 99 $0.00
J2919 Injection, methylprednisolone sodium succinate, 5 mg 0% 81 $0.00
91300 0% 19 $0.00
80179 0% 17 $0.00
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals 0% 42 $0.00
94799 0% 14 $0.00
84520 0% 13 $0.00
G8783 Normal blood pressure reading documented, follow-up not required 0% 24 $0.00
G8952 Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given 0% 251 $0.00
J1100 Injection, dexamethasone sodium phosphate, 1 mg 0% 109 $0.00
ATP23 0% 29 $0.00
95851 0% 147 $0.00
G8950 Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented 0% 26 $0.00
J2765 Injection, metoclopramide hcl, up to 10 mg 0% 31 $0.00
J1010 Injection, methylprednisolone acetate, 1 mg 0% 21 $0.00
88342 0% 50 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSULLIVAN, THOMAS (CEO)
Parent organizationHEYWOOD HEALTHCARE INC
Same official

Other billing entities under SULLIVAN, THOMAS

Full network →
ProviderLocationPaid
Henry Heywood Memorial HospitalGardner, MA$54.50M
Heywood Medical Group INC.Gardner, MA$4.22M
Heywood Affiliated Medical Group INC.Gardner, MA$734K
Heywood Medical Group INCAthol, MA$436K
Athol Memorial Hospital IncorporatedAthol, MA$162K
Athol Memorial Hospital IncorporatedAthol, MA$52K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.